Prevention of hepatitis A through active or passive immunization; recommendations of the Advisory Committee on Immunization Practices (ACIP)
Published Date:December 27, 1996
Source:MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1996; 45(RR-15):1-30.
Corporate Authors:United States, Advisory Committee on Immunization Practices ; Centers for Disease Control and Prevention (U.S.) ; National Center for Infectious Diseases (U.S.), Division of Viral and Rckettsial Diseases.
Keywords:Administration & Dosage
Hepatitis A Vaccines
Prevention & Control
Hepatitis A/Prevention & Control
Hepatitis A Vaccines/Administration & Dosage
Immunization, Passive/Standards/United States
Series:MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 45, no. RR-15
Description:This report provides recommendations for use of the newly licensed hepatitis A vaccines (HAVRIX, manufactured by SmithKline Beecham Biologicals, and VAQTA, manufactured by Merck & Company, Inc.) in persons > or = 2 years of age and updates previous recommendations for use of immune globulin (IG) for protection against hepatitis A (superseding MMWR 1990;39[No. RR-2]:1-5). For preexposure protection, hepatitis A vaccine can now be used instead of IG in many circumstances; for postexposure prophylaxis, the recommendations for IG use are unchanged.
Supporting Files:No Additional Files
You May Also Like: